XXXX therapy in @entity1577 .

@entity1 @entity137 @entity1987 @entity2890 @entity3405 @entity4028 @entity17286 @entity2177 @entity281 @entity166 @entity1577
There is great need for an oral agent that could be used to treat pulmonary exacerbations in @entity1 with @entity1577 . In this study, the use of oral @entity2177 as sole therapy was evaluated in 18 @entity1 with 39 @entity166 episodes; 13 episodes were classified as severe, 19 were classified as moderate, and seven were classified as mild. @entity1 ranged in age from eight to 36 years (mean, 23 years). Dosage varied according to severity of disease, body size, and the susceptibility of the Pseudomonas isolate to @entity2177 ; the dose ranged from 750 to 2,250 mg daily (mean, 1,800 mg). Ten @entity1 received one course of @entity2177 , and eight received repeated courses. The overall clinical response rate was 82 percent. There was a response to the initial treatment course in 96 percent of the @entity1 . Those in whom therapy failed had been re-treated with @entity2177 and were severely ill. Failure to respond correlated poorly with pretreatment @entity1987 ( @entity1987 ) values (0.6 microgram/ml for failures versus 0.4 microgram/ml for responses). Pseudomonas could not be eradicated from the sputum of any of the @entity1 , although there was a marked reduction in purulence and bacterial counts. In general, @entity1 who did not require re-treatment for three months would again have susceptible organisms. When organisms became resistant to @entity2177 ( @entity1987 greater than 2 micrograms/ml), they showed no concomitant new @entity4028 or @entity3405 resistance. No serious @entity137 occurred in any of the 39 episodes of treatment. In seven @entity1 treated with combination therapy ( @entity2890 or @entity17286 ), the infecting organisms were reduced in number, but eradication of Pseudomonas generally could not be achieved. Increases in @entity1987 occurred during combination therapy. @entity2177 is a major advance in the treatment of @entity281 in @entity1 with @entity1577 .
